October 2, 2019
Taisho Pharmaceutical has inked an exclusive licensing pact with Sweden’s Moberg Pharma for the development and commercialization of its investigational onychomycosis treatment MOB-015 in Japan, the company said on October 1. Developed based on Moberg’s proprietary technology, MOB-015 is a...read more